Pacira Biosciences (NASDAQ:PCRX) Releases Quarterly Earnings Results

Share on StockTwits

Pacira Biosciences (NASDAQ:PCRX) posted its quarterly earnings results on Thursday. The company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.35, Briefing.com reports. The business had revenue of $104.69 million during the quarter, compared to the consensus estimate of $104.88 million. Pacira Biosciences had a net margin of 2.04% and a return on equity of 8.62%. The company’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 earnings per share.

Shares of Pacira Biosciences stock traded up $1.40 during trading on Friday, hitting $44.02. 711,200 shares of the stock were exchanged, compared to its average volume of 631,161. Pacira Biosciences has a 12-month low of $34.64 and a 12-month high of $50.90. The company has a debt-to-equity ratio of 0.99, a current ratio of 4.75 and a quick ratio of 4.12. The firm’s 50-day moving average price is $39.20 and its 200 day moving average price is $41.12. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 151.79, a price-to-earnings-growth ratio of 1.96 and a beta of 1.13.

In other Pacira Biosciences news, CEO David M. Stack sold 12,849 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $39.15, for a total transaction of $503,038.35. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kristen Marie Williams sold 6,252 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total transaction of $246,891.48. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

Several research firms have recently issued reports on PCRX. BMO Capital Markets decreased their price objective on shares of Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating for the company in a research report on Friday, August 9th. BidaskClub raised shares of Pacira Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday. Cowen reaffirmed a “hold” rating and set a $41.00 price objective on shares of Pacira Biosciences in a research report on Thursday. Stifel Nicolaus set a $42.00 price objective on shares of Pacira Biosciences and gave the stock a “hold” rating in a research report on Friday, August 9th. Finally, BTIG Research began coverage on shares of Pacira Biosciences in a research report on Wednesday. They set a “buy” rating and a $56.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. Pacira Biosciences currently has an average rating of “Hold” and an average price target of $52.55.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Recommended Story: What are the benefits of buying treasury bonds?

Earnings History for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Anticipate First Bancorp  Will Post Quarterly Sales of $70.13 Million
Zacks: Analysts Anticipate First Bancorp Will Post Quarterly Sales of $70.13 Million
Pacira Biosciences  Releases Quarterly  Earnings Results
Pacira Biosciences Releases Quarterly Earnings Results
Jounce Therapeutics  Issues Quarterly  Earnings Results
Jounce Therapeutics Issues Quarterly Earnings Results
$0.23 Earnings Per Share Expected for Crawford & Company  This Quarter
$0.23 Earnings Per Share Expected for Crawford & Company This Quarter
Whitnell & Co. Acquires 3,275 Shares of TJX Companies Inc
Whitnell & Co. Acquires 3,275 Shares of TJX Companies Inc
Taylor Hoffman Wealth Management Increases Stock Position in Hershey Co
Taylor Hoffman Wealth Management Increases Stock Position in Hershey Co


© 2006-2019 Ticker Report